< back to search

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega, Helena   •   Sieper, Joachim   •   Kivitz, Alan   •   Blanco, Ricardo   •   Cohen, Martin   •   Delicha, Evie-Maria   •   Rohrer, Susanne   •   Richards, Hanno

published in: RMD open



endpoint

Secukinumab has (optional: compared with placebo) proved to be better.
general condition better


publication details

10.1136/rmdopen-2017-000592
pubmed
29435364
2017
Journal Article
randomized controlled trial
yes
prospective
1+

▼
▲